First-line remissions and SCT for patients without known preclusions to intensive induction chemotherapy.

Strong remissions were seen in 56 additional patients in the pivotal trials who 1:

  • Did not have known comorbidities that preclude the use of intensive induction chemotherapy; and
  • Received VEN + AZA (n=17) or VEN + DEC (n=18) (ages 65 to 74 years) (in Study M14-358); or
  • Received VEN + LDAC (n=21) (ages 67 to 74 years) (in Study M14-387)

VENCLEXTA  + azacitidine (VEN + AZA)

VENCLEXTA + decitabine (VEN + DEC)

VENCLEXTA + low-dose cytarabine (VEN + LDAC)

CR=complete remission; CRh=complete remission with partial hematologic recovery; SCT=stem cell transplant.

*The primary patient population was defined as patients ≥75 years of age, or patients who had comorbidities that precluded the use of intensive induction chemotherapy based on at least one of the following criteria: baseline ECOG performance status of 2-3, severe cardiac or pulmonary comorbidity, moderate hepatic impairment, CLcr <45 mL/min, or other comorbidity.